Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors

被引：0
|
作者：
Castello, A. [1 ]
Rossi, S. [1 ]
Toschi, L. [1 ]
Lopci, E. [1 ]
机构：
[1] Humanitas Clin & Res Hosp, Rozzano, MI, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-024
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [1] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
    Castello, Angelo
    Rossi, Sabrina
    Toschi, Luca
    Mansi, Luigi
    Lopci, Egesta
    CANCERS, 2020, 12 (06)
  • [2] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [3] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [4] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [5] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
    Minari, Roberta
    Bonatti, Francesco
    Mazzaschi, Giulia
    Dodi, Alessandra
    Facchinetti, Francesco
    Gelsomino, Francesco
    Cinquegrani, Gloria
    Squadrilli, Anna
    Bordi, Paola
    Buti, Sebastiano
    Bersanelli, Melissa
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Quaini, Federico
    Ardizzoni, Andrea
    Tiseo, Marcello
    TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
  • [6] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [7] Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
    Zhou, Jun
    Mahoney, Kathleen M.
    Giobbie-Hurder, Anita
    Zhao, Fengmin
    Lee, Sandra
    Liao, Xiaoyun
    Rodig, Scott
    Li, Jingjing
    Wu, Xinqi
    Butterfield, Lisa H.
    Piesche, Matthias
    Manos, Michael P.
    Eastman, Lauren M.
    Dranoff, Glenn
    Freeman, Gordon J.
    Hodi, F. Stephen
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (06) : 480 - 492
  • [8] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
  • [9] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [10] Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
    Ando, Kiyohiro
    Hamada, Kazuyuki
    Watanabe, Makoto
    Ohkuma, Ryotaro
    Shida, Midori
    Onoue, Rie
    Kubota, Yutaro
    Matsui, Hiroto
    Ishiguro, Tomoyuki
    Hirasawa, Yuya
    Ariizumi, Hirotsugu
    Tsurutani, Junji
    Yoshimura, Kiyoshi
    Tsunoda, Takuya
    Kobayashi, Shinichi
    Wada, Satoshi
    ANTICANCER RESEARCH, 2019, 39 (09) : 5195 - 5201
12345